For Thursday
September 4th, 2008
THIS JUST IN....
Techalt, Inc. Announces Launch of Rim-Ice Product at the 2008 BMW Z-3 and Z-4 Homecoming
SEATTLE--(BUSINESS WIRE)--Techalt, Inc. (Pink Sheets: TCLT) ("Techalt" or "Company") announced the introduction of its Rim-Ice product at the Twelfth Annual 2008 BMW Homecoming for the BMW Z-3 and Z-4 roadsters in Greenville, SC. Consumers and dealers alike are buzzing about the product, its uniqueness in the market, and how much better it works compared to similar products. Distributors and dealers alike are providing positive feedback during the promo-giveaway. This annual pilgrimage is for the BMW car enthusiast and attracts thousands of people looking for the latest and greatest products to enhance the beauty of their automobile. Techalt believes Rim-Ice fits that bill.
Jay Lilley, the Parts Director for a high-end dealership in Tampa, Florida, has been going to the BMW Homecoming for 12 years, and is one of the “The Original Twelve,” and has been carrying Rim-Ice for the past 2 years. Upon becoming Parts Director in Tampa, he integrated the product into their dealership inventory and received positive feedback. Similarly, the response at the BMW Homecoming has been incredible.
People are curious about ways to keep their wheels and chrome clean longer. At the BMW Homecoming event, over 11 cases of sample product, including marketing material, were handed out. Many representatives from the BMW Greenville Manufacturing plant offices were on hand at the BMW Homecoming Event, as well as representatives from Coachworks, Wheel and Rim magazines. All of these groups expressed interest in Rim-Ice and took samples, indicating there is a strong need in the market for Rim-Ice. Each one admitted there is a lack of a quick and easy-to-use, quality product that reduces brake dust and shines up chrome for the car enthusiast.
This market is untapped, per a senior representative of Coachworks, who believes there is an opportunity to generate approximately $20 million dollars of revenue per year by selling Rim-Ice through the Coachworks distribution system. Coachworks purchased a case of the product. Coachworks is looking to offer Rim-Ice through their catalog as the newest and fastest way to keep cars or motorcycles sparkling. Additionally, a president of a motorcycle chassis-building company indicated that there is a need for a quick chrome product that shines bikes fast -- Rim-Ice may be the solution to that problem.
Techalt believes the marketing research and visibility gained from introducing the Rim-Ice product at the BMW Homecoming was exceptional. Jeff Braswell of “South Atlanta BMW”, who has been stocking Rim-Ice in their parts department for 5 years, stated, “A product such as this, to reduce break dust, will make millions!”
Dave Moore, President and CEO of Techalt, commented, “I’m very excited with the reception we received at the Z-3/Z-4 Homecoming. This confirms that Rim-Ice is an excellent addition to our portfolio of products at Techalt.”
About Gorlen, Inc./Rim-Ice:
Rim-Ice is a consumer product designed and developed by Gorlen, Inc (“Gorlen”). Gorlen is a specialty chemical company which specializes in the innovative design and development of new consumer products for the automotive industry.
About Techalt:
Techalt, a holding company, dedicated to acquiring, licensing and financing start-up and mid-stage companies. Techalt focuses on innovative, alternative technologies, software, communications, environmental and health and wellness sectors.
About Stan’s Rodeo Ointment (“SRO”):
SRO is a sports cream product designed to accelerate the healing time for abrasions, lacerations, blisters and other open wounds to the skin, while diminishing the pain that often results from such injuries. Developed by Stanley Johnston, former head athletic trainer for the Los Angeles Dodgers, SRO is currently available by prescription and used by several prominent Olympic and professional athletes. Techalt also acquired the rights to develop Stan’s Blister Rub (“SBR”), which is a combination of materials that strengthen the skin after it has healed to reduce the likelihood of the reoccurrence of blisters to the applied area. Patent protection has been filed covering the formulations and processing of SRO with the US Patent and Trademark Office with a patent expected in August 2008.
RECENT DEVELOPMENTS
Stan Johnson and Techalt representatives will make its first appearance as a standalone product at the 2008 National Athletic Trainers Association Annual Meeting in St. Louis, MO June 17 – 21, 2008. Stanley Johnston will be present at the conference to answer questions regarding specific uses and benefits of SRO. The conference is deemed the largest convention attended by athletic trainers, physicians, physical therapists and other medical personnel in the United States.
About the National Athletic Trainers' Association (NATA):
Athletic trainers are unique health care professionals who specialize in the prevention, diagnosis, treatment and rehabilitation of injuries and illnesses. The National Athletic Trainers' Association represents and supports 30,000 members of the athletic training profession. NATA advocates for equal access to athletic trainers for patients and clients of all ages and supports H.R. 1846. Only 42 percent of high schools have access to athletic trainers. NATA members adhere to a code of ethics. www.nata.org.
SRO USES
BLISTERS
Blisters themselves can cause other more serious problems when an athlete adjusts his or her movements in reaction to the pain caused by the blister. For example, Mark Hubbard, president of American Specialty Underwriters, a leading baseball insurer, found that blisters sometimes cause pitchers to adjust their throwing mechanics just enough to expose them to more serious shoulder or elbow injuries. Due to the high cost of disabled pitchers (some costing $100 million a year in wasted salary), some teams will avoid such expense and pull the pitcher before the blister causes such problems.
While Neosporin® and other polysporin agents on the market provide antibiotic therapy for cuts and abrasion, there is virtually no other product on the market today other than SRO that has successfully targeted blister related injuries. Blisters are a common problem for other sports, including tennis, gymnastics, baseball, weightlifting, ballet, etc.
By applying SRO to blisters, pitchers are able to play without adjusting form or ball grip. Over twenty professional baseball teams use SRO and have expressed tremendous satisfaction with the product and suggested that it is the only product from which they have found an adequate remedy for the blisters. Ballet teachers and coaches have voiced similar concerns over blisters and have found similar successes with SRO. It is not uncommon for ballet dancers to continue their practice with broken toes and blisters commonly left open and raw. SRO protects the blister and toughens the skin while providing an antibiotic treatment to prevent infection.
ROAD RASH & ABRASIONS
Studies indicate that road rash and abrasions constitute another common use of SRO. On average, sports medicine physicians see at least eight to twenty patients per week who suffer from carpet burn, road rash and various abrasions.
By targeting road rash, SRO hopes to establish itself in a specific niche of the market, which like the blister market, has been neglected. The goal of road rash therapy is to seal and heal the injury. Commonly, a player will be prevented from playing because his wound reopens and begins to bleed. Athletic regulation prohibits any player from continued play where the wound continues to bleed. Current therapy options include local dressing and topical antibiotics, neither of which has proven successful. SRO, however, covers the entire injury and seals it, preventing any blood to escape while simultaneously acting to heal the wound.
SIDE EFFECTS
Toxicological studies have found no significant adverse side effects. Consumers using SRO have indicated minimal local discomfort when administered, while some say they have used SRO ritualistically without any problems whatsoever. Other potential side effects may include a stain on clothing.
COMPETITION
According to some within the industry, the size of the wound care market is approximately $150 million per year. Mr. Johnston believes there is no other existing compound or product, either synthetic or naturally occurring, which has reported similar biochemical actions and properties, i.e., successfully sealing the wound while preventing oozing of blood and decreasing healing time. Current therapies include wound dressing and antibiotic treatment, neither of which offers superior remedy. Existing products on the market used to treat these types of injuries include Neosporin® and Bacitracin®.
STAN'S BLISTER RUB
Mr. Johnston has developed a product to compliment SRO, commonly known as “Stan’s Blister Rub” (“SBR”), a wet sand-like texture which is designed to be applied after usage of SRO in order to toughen the skin following the healing of blisters to prevent further blisters and irritations.
PRODUCTION
SRO and SBR are currently being compounded by Living Well Pharmacy Inc., d/b/a HNP Pharmaceuticals (“Living Well”), a pharmaceutical compounding laboratory that compounds medications by prescription. Living Well has a non-exclusive license to directly compound SRO and SBR on a prescription basis. Living Well currently receives 33% of the aggregate gross sales of all SRO and SBR compounded by Living Well during each calendar quarter.
MARKETING AND SALES
SRO is currently available in a prescription formula, with the intent on obtaining over the counter (“OTC”) certification within the next 24-36 months. Current revenue is $60,000 per year, with current marketing activities consisting solely of “word of mouth”. With a definitive sales and marketing plan currently being developed by Techalt, it is believed new exposure will lead to an increase in SRO’s sales due to an expanded customer base.
Techalt is currently in the process of identifying local test markets to conduct focus groups regarding and perform demonstrations of SRO to expand its marketing and brand awareness.
About Techalt:
BACKGROUND
Stan’s Rodeo Ointment (“SRO”) is a new chemical agent for sport-related injuries that significantly shortens the healing time for abrasions, lacerations and blisters, while diminishing the pain that is often related to such injuries. Developed by a former professional rodeo rider and major league baseball head trainer, SRO is used by athletes competing on the high school, collegiate, Olympic and professional levels, as well as those individuals commonly known as the “weekend warriors.” This new remedy, currently available on a prescription basis, allows athletes of all ages to “play on through” some of the more common injuries without jeopardizing their athletic capacities.
Originally developed in 1980, SRO accelerates the healing time associated with blisters, abrasions, incisions, lacerations and open wounds to the skin by applying a combination of the following active ingredients: Bacitracin, Polymyxin, Tincture of Benzoin, Povidone Iodine, Phenylephrine, 8-hydroxyquinoline, Ichthammol and Hydrocortisone. Feedback from athletes suggest SRO reduces the healing time of dermal wounds by anywhere from one-third to one-half the normal time.
SRO was developed by Stanley Johnston (“Mr. Johnston”), a former professional rodeo rider who also served as Head Trainer for the Los Angeles Dodgers and spent 23 years with the organization. While competing on the professional rodeo tour, Mr. Johnston endured countless injuries, none more prevalent than the hand blisters he suffered which would tear the skin from his riding hand. Finding no successful remedy on the market, Mr. Johnston decided to create his own remedy and developed what athletes throughout the country now know as “Stan’s Rodeo Ointment.” Mr. Johnston has sold batches of SRO to twenty Major League Baseball clubs and it is estimated that at least two dozen professional pitchers use SRO on a regular basis.
While SRO has found perhaps its greatest success among the professional baseball leagues, Mr. Johnston, through his licensing of SRO to Techalt, Inc., a Nevada corporation (“Techalt” or the “Company”), now seeks to expand SRO’s usage among professional athletes and those athletes competing on all competition levels, in addition to the continually expanding “weekend athletes” market.
Various newspapers and sports, health and business periodicals around the Country have reported on SRO’s success, which has led to an increase in sales. With this media foundation already laid, Techalt intends to expand SRO’s marketing, which will include testimonials and endorsements from several Olympic and professional athletes and medical professionals.
An application for patent protection has been filed covering the formulations and processing of SRO with the US Patent and Trademark Office.
INVENTOR BACKGROUND
Stanley Johnston. Mr. Johnston is the inventor of SRO and SBR. Mr. Johnston is currently a retired Certified Athletic Trainer, most recently with the Los Angeles Dodgers, where he served as an athletic trainer for 23 years, including several years as Head Athletic Trainer. Prior to working with the Dodgers, Mr. Johnston was a professional rodeo competitor for 10 years. Mr. Johnston has been an innovator of many products and techniques utilized in the Sports Medicine field. Having worked on the high school, collegiate and professional levels, Mr. Johnston knows what it takes to make an athlete reach his or her full potential. Mr. Johnston earned a degree in physical education with an emphasis in sports medicine at Western Montana College and a master’s degree from Montana State University.
Company Essentials:
Symbol |
TCLT |
Stock Price Open |
$0.0001 Volume:47,283,000 |
52 Week Range |
|
Website |
|
Quote |
|
DISCLAIMER:
This profile is not without bias, and is a paid release. IWSR has been compensated for dissemination of company information on behalf of a third party. (IWSR has been compensated a total 19k cash and 75,000,000 Free Trading Shares for coverage of Techalt, Inc. (Pink Sheets:TCLT) from a third party. IWSR may receive shares for extension of its services. Any shares will be disclosed at such time that IWSR is aware of a clients desire to extend the original services. IWSR may have received shares of a company profiled in this release prior to the dissemination of the information in this release. IWSR may immediately sell some or any shares in a profiled company held by IWSR and may have previously sold shares in a profiled company held by IWSR. IWSR's services for a company may cause the company's stock price to increase, in which event IWSR would make a profit when it sells its stock in a company. In addition, IWSR's selling of a company's stock may have a negative effect on the market price of the stock.
This release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. "Forward-looking statements" describe future expectations, plans, results, or strategies and are generally preceded by words such as “may”, "future", "plan" or "planned", "will" or "should", "expected," "anticipates", "draft", "eventually" or "projected". You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in a companies' annual report on Form 10-K or 10-KSB and other filings made by such company with the Securities and Exchange Commission. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and IWSR undertakes no obligation to update such statements. |